David Jw Grant

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11444410/publications.pdf

Version: 2024-02-01

68 papers	4,600 citations	101543 36 h-index	106344 65 g-index
68 all docs	68 docs citations	68 times ranked	2975 citing authors

#	Article	IF	Citations
1	Stable-Form Screening: Overcoming Trace Impurities That Inhibit Solution-Mediated Phase Transformation to the Stable Polymorph of Sulfamerazine. Journal of Pharmaceutical Sciences, 2008, 97, 2130-2144.	3.3	37
2	A Calorimetric Investigation of Thermodynamic andMolecular Mobility Contributions to the Physical Stability of Two Pharmaceutical Glasses. Journal of Pharmaceutical Sciences, 2007, 96, 71-83.	3.3	55
3	Influence of crystal structure on the tableting properties of nâ€alkyl 4â€hydroxybenzoate esters (parabens). Journal of Pharmaceutical Sciences, 2007, 96, 3324-3333.	3.3	46
4	Principles of Solubility. , 2007, , 1-27.		8
5	Physical properties and enantiomeric composition. , 2006, , 47-77.		2
6	N4-Acetylsulfamerazine. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o4245-o4246.	0.2	1
7	Identifying the Stable Polymorph Early in the Drug Discoveryâ€“Development Process. Pharmaceutical Development and Technology, 2005, 10, 291-297.	2.4	93
8	Quantitation of crystalline and amorphous forms of anhydrous neotame using 13C CPMAS NMR spectroscopy. Journal of Pharmaceutical Sciences, 2005, 94, 2591-2605.	3.3	73
9	Relationship between the Structure and Properties of Pharmaceutical Crystals. KONA Powder and Particle Journal, 2005, 23, 36-48.	1.7	37
10	Solidâ€state properties of warfarin sodium 2â€propanol solvate. Journal of Pharmaceutical Sciences, 2004, 93, 2669-2680.	3.3	17
11	Dehydration kinetics of piroxicam monohydrate and relationship to lattice energy and structure. Journal of Pharmaceutical Sciences, 2004, 93, 3013-3026.	3.3	56
12	Crystal structures of the benzene and ethanol solvates of neotame. Journal of Chemical Crystallography, 2003, 33, 787-793.	1.1	1
13	Racemic species of sodium ibuprofen: Characterization and polymorphic relationships. Journal of Pharmaceutical Sciences, 2003, 92, 1356-1366.	3.3	51
14	Model-free treatment of the dehydration kinetics of nedocromil sodium trihydrate. Journal of Pharmaceutical Sciences, 2003, 92, 1367-1376.	3.3	48
15	Crystallization Kinetics of Amorphous Nifedipine Studied by Model-Fitting and Model-Free Approaches. Journal of Pharmaceutical Sciences, 2003, 92, 1779-1792.	3.3	83
16	Crystallization and Transitions of Sulfamerazine Polymorphs. Journal of Pharmaceutical Sciences, 2002, 91, 1089-1100.	3.3	108
17	Dehydration kinetics of neotame monohydrate. Journal of Pharmaceutical Sciences, 2002, 91, 1423-1431.	3.3	35
18	Physical Stability of Amorphous Pharmaceuticals: Importance of Configurational Thermodynamic Quantities and Molecular Mobility. Journal of Pharmaceutical Sciences, 2002, 91, 1863-1872.	3.3	292

#	Article	IF	Citations
19	Conformational flexibility and hydrogenâ€bonding patterns of the neotame molecule in its various solid forms. Journal of Pharmaceutical Sciences, 2002, 91, 2047-2056.	3.3	2
20	Crystal structure and thermal behavior of nedocromil nickel octahydrate. International Journal of Pharmaceutics, 2002, 232, 23-33.	5.2	9
21	Stabilization of a metastable polymorph of sulfamerazine by structurally related additives. Journal of Crystal Growth, 2002, 235, 471-481.	1.5	81
22	Dehydration behavior of nedocromil magnesium pentahydrate. International Journal of Pharmaceutics, 2001, 215, 251-262.	5.2	25
23	Effects of initial particle size on the tableting properties of l-lysine monohydrochloride dihydrate powder. International Journal of Pharmaceutics, 2001, 215, 221-228.	5.2	101
24	Estimating the relative stability of polymorphs and hydrates from heats of solution and solubility data. Journal of Pharmaceutical Sciences, 2001, 90, 1277-1287.	3.3	100
25	Molecular Modeling Study Of Chiral Drug Crystals: Lattice Energy Calculations. Journal of Pharmaceutical Sciences, 2001, 90, 1523-1539.	3.3	51
26	Polymorph screening: Influence of solvents on the rate of solvent-mediated polymorphic transformation. Journal of Pharmaceutical Sciences, 2001, 90, 1878-1890.	3.3	263
27	Hydrogen bonding in sulfonamides. Journal of Pharmaceutical Sciences, 2001, 90, 2058-2077.	3.3	167
28	Influence of Crystal Shape on the Tableting Performance of Lâ€Lysine Monohydrochloride Dihydrate. Journal of Pharmaceutical Sciences, 2001, 90, 569-579.	3.3	73
29	Crystalline solids. Advanced Drug Delivery Reviews, 2001, 48, 3-26.	13.7	625
30	Polymorph screening: Influence of solvents on the rate of solventâ€mediated polymorphic transformation. Journal of Pharmaceutical Sciences, 2001, 90, 1878-1890.	3.3	197
31	Investigation of Polymorphism in Aspartame and Neotame Using Solid-State NMR Spectroscopy. Tetrahedron, 2000, 56, 6603-6616.	1.9	34
32	Title is missing!. Pharmaceutical Research, 2000, 17, 1439-1442.	3.5	0
33	Characterization of Racemic Species of Chiral Drugs Using Thermal Analysis, Thermodynamic Calculation, and Structural Studies. Journal of Pharmaceutical Sciences, 1999, 88, 337-346.	3.3	107
34	Dehydration behavior of eprosartan mesylate dihydrate. Journal of Pharmaceutical Sciences, 1999, 88, 1021-1029.	3.3	30
35	Physical properties of parabens and their mixtures: Solubility in water, thermal behavior, and crystal structures. Journal of Pharmaceutical Sciences, 1999, 88, 1210-1216.	3.3	85
36	Solid-state behavior of cromolyn sodium hydrates. Journal of Pharmaceutical Sciences, 1999, 88, 1191-1200.	3.3	65

#	Article	IF	Citations
37	Crystal structure and physical characterization of neotame methanol solvate. Journal of Chemical Crystallography, 1999, 29, 967-975.	1.1	9
38	Solid-State Characterization of Two Polymorphs of Aspartame Hemihydrate. Journal of Pharmaceutical Sciences, 1998, 87, 501-507.	3.3	46
39	Hydration and Dehydration Behavior of Aspartame Hemihydrate. Journal of Pharmaceutical Sciences, 1998, 87, 508-513.	3.3	37
40	Physical characterization of nedocromil sodium hydrates. Journal of Pharmaceutical Sciences, 1998, 87, 1052-1061.	3.3	41
41	Crystallisation of paracetamol (acetaminophen) in the presence of structurally related substances. Journal of Crystal Growth, 1998, 183, 629-640.	1.5	70
42	Solid State Stability Studies of Model Dipeptides: Aspartame and Aspartylphenylalanine. Journal of Pharmaceutical Sciences, 1997, 86, 64-71.	3.3	56
43	Physicochemical Characterization of Nedocromil Bivalent Metal Salt Hydrates. 2. Nedocromil Zinc. Journal of Pharmaceutical Sciences, 1997, 86, 418-429.	3.3	30
44	Relationship Between Physical Properties and Crystal Structures of Chiral Drugs. Journal of Pharmaceutical Sciences, 1997, 86, 1073-1078.	3.3	81
45	Effects of crystallization in the presence of the opposite enantiomer on the crystal properties of (ss)-(+)-pseudoephedrinium salicylate. International Journal of Pharmaceutics, 1996, 127, 53-63.	5.2	18
46	Influence of water activity in organic solvent + water mixtures on the nature of the crystallizing drug phase. 2. Ampicillin. International Journal of Pharmaceutics, 1996, 139, 33-43.	5.2	101
47	Effects of excess enantiomer on the crystal properties of a racemic compound: ephedrinium 2-naphthalenesulfonate. International Journal of Pharmaceutics, 1996, 137, 21-31.	5.2	18
48	Physicochemical Characterization of Nedocromil Bivalent Metal Salt Hydrates. 1. Nedocromil Magnesium. Journal of Pharmaceutical Sciences, 1996, 85, 1026-1034.	3.3	37
49	Relationships between Solution Thermodynamics and Hydrogenâ€Bond Patterns of Crystalline Dialkylhydroxypyridone Iron Chelators and Their Formic Acid Solvates. Journal of Pharmaceutical Sciences, 1995, 84, 568-574.	3.3	4
50	The effect of structurally related substances on the nucleation kinetics of paracetamol (acetaminophen). Journal of Crystal Growth, 1995, 156, 252-260.	1.5	63
51	The use of thermal analysis in the assessment of crystal disruption. Thermochimica Acta, 1995, 248, 131-145.	2.7	38
52	Pharmaceutical hydrates. Thermochimica Acta, 1995, 248, 61-79.	2.7	459
53	Determination of the solubilities of crystalline solids in solvent media that induce phase changes: Solubilities of 1,2-dialkyl-3-hydroxy-4-pyridones and their formic acid solvates in formic acid and water. International Journal of Pharmaceutics, 1995, 114, 185-196.	5.2	20
54	Effect of the opposite enantiomer on the physicochemical properties of (-) -ephedrinium 2-naphthalenesulfonate crystals. International Journal of Pharmaceutics, 1993, 94, 171-179.	5.2	20

#	Article	IF	Citations
55	Determination of water content in pharmaceutical hydrates by differential scanning calorimetry. International Journal of Pharmaceutics, 1992, 82, 117-127.	5.2	62
56	Solid State Properties of an Oral Iron Chelator, 1,2-Dimethyl-3-hydroxy-4-pyridone, and Its Acetic Acid Solvate. I: Physicochemical Characterization, Intrinsic Dissolution Rate, and Solution Thermodynamics. Journal of Pharmaceutical Sciences, 1991, 80, 677-685.	3.3	18
57	Physical factors influencing the aqueous dissolution rate of acetaminophen crystals doped with p-acetoxyacetanilide: evaluation by multiple linear regression. International Journal of Pharmaceutics, 1989, 51, 129-135.	5.2	16
58	Influence of compaction on the intrinsic dissolution rate of modified acetaminophen and adipic acid crystals. International Journal of Pharmaceutics, 1989, 57, 117-124.	5.2	43
59	Influence of crystallization conditions on the physical properties of acetaminophen crystals: evaluation by multiple linear regression. International Journal of Pharmaceutics, 1989, 51, 115-127.	5.2	11
60	Modification of acetaminophen crystals. II. Influence of stirring rate during solution-phase growth on crystal properties in the presence and absence of p-acetoxyacetanilide. International Journal of Pharmaceutics, 1988, 41, 29-39.	5.2	13
61	Modification of acetaminophen crystals. III. Influence of initial supersaturation during solution-phase growth on crystal properties in the presence and absence of p-acetoxyacetanilide. International Journal of Pharmaceutics, 1988, 42, 123-133.	5.2	23
62	Enthalpyâ€"entropy compensation in pharmaceutical solids. International Journal of Pharmaceutics, 1987, 40, 1-14.	5.2	21
63	Locating the impurity in doped crystals using isotopic double labelling and a column â€œflow-throughâ€• dissolution cell: adipic acid doped with oleic acid. International Journal of Pharmaceutics, 1987, 36, 17-28.	5.2	8
64	A theoretical treatment of changes in energy and entropy of solids caused by additives or impurities in solid solution. International Journal of Pharmaceutics, 1987, 39, 243-253.	5.2	18
65	A disruption index for quantifying the solid state disorder induced by additives or impurities. II. Evaluation from heat of solution. International Journal of Pharmaceutics, 1986, 28, 103-112.	5.2	44
66	Entropy of processing: a new quantity for comparing the solid state disorder of pharmaceutical materials. International Journal of Pharmaceutics, 1986, 30, 161-180.	5.2	36
67	True density and thermal expansivity of pharmaceutical solids: comparison of methods and assessment of crystallinity. International Journal of Pharmaceutics, 1986, 28, 75-84.	5.2	36
68	A disruption index for quantifying the solid state disorder induced by additives or impurities. I. Definition and evaluation from heat of fusion. International Journal of Pharmaceutics, 1985, 25, 57-72.	5.2	45